Sato Yuhki, Tokimatsu Issei, Suzuki Yosuke, Itoh Hiroki, Hiramatsu Kazufumi, Kadota Jun-ichi
Department of Clinical Pharmacy, Oita University Hospital, Yufu, Japan.
Chemotherapy. 2014;60(4):274-8. doi: 10.1159/000381634. Epub 2015 Apr 25.
Teicoplanin (TEIC) is a glycopeptide currently used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). A plasma trough concentration (Cmin) of >20 mg/l should be used for severe infections. The aim of this study was to assess the efficacy, safety and use of Cmin >20 mg/l on day 4-6 in patients with complicated MRSA infections.
Blood samples were drawn from the 41 included patients just before TEIC administration between day 4 and 6. The patients were divided into three groups (group A: >20 mg/l, group B: 10-20 mg/l and group C: <10 mg/l) based on their Cmin on day 4-6.
Differences in efficacy between the groups were significant, but differences in safety were not. The patients in group A required lower cumulative doses than those in either groups B or C.
The optimal clinical efficacy and safety might be associated with TEIC Cmin on the fourth to sixth day.
替考拉宁（TEIC）是一种糖肽类药物，目前用于治疗耐甲氧西林金黄色葡萄球菌（MRSA）感染。对于严重感染，应使用血浆谷浓度（Cmin）>20mg/L的标准。本研究的目的是评估在患有复杂性MRSA感染的患者中，第4至6天Cmin>20mg/L的疗效、安全性及应用情况。
在第4至6天替考拉宁给药前，采集41例纳入研究患者的血样。根据第4至6天的Cmin，将患者分为三组（A组：>20mg/L，B组：10 - 20mg/L，C组：<10mg/L）。
各组间疗效差异显著，但安全性差异不显著。A组患者所需的累积剂量低于B组或C组患者。
最佳临床疗效和安全性可能与第4至6天的替考拉宁Cmin有关。
